Ironwood Q3 LINZESS sales up 40% YoY to $315M; raises full-year guidance

IRONWOOD PHARMACEUTICALS INC

2025-Q3 EPS reported $0.16 vs consensus $0.10 ▲ beat (+56.9%)

Q3 GAAP net income $40M ($0.23 diluted EPS) vs $3.6M a year ago; adjusted EBITDA $82M vs $34.5M.
LINZESS US net sales $315M (+40% YoY); EUTRx demand growth +12% YoY.
Raises FY2025 LINZESS net sales guidance to $860-$890M; total revenue $290-$310M; adjusted EBITDA >$135M.
FDA approved LINZESS for IBS-C in children ages 7+; first drug for that indication.
Plans to align with FDA on apraglutide Phase 3 trial design, start confirmatory study H1 2026; strategic alternatives review ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.